Novolog Flexpen is a drug owned by Novo Nordisk Inc. It is protected by 12 US drug patents filed from 2013 to 2019. Out of these, 1 drug patents are active and 11 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2032. Details of Novolog Flexpen's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Novolog Flexpen's patents.

Latest Legal Activities on Novolog Flexpen's Patents

Given below is the list of recent legal activities going on the following patents of Novolog Flexpen.

Activity	Date	Patent Number
Today's Critical Events
Payment of Maintenance Fee, 12th Year, Large Entity	16 Dec, 2021	US7762994
Payment of Maintenance Fee, 8th Year, Large Entity	22 Apr, 2021	US8579869
Payment of Maintenance Fee, 8th Year, Large Entity	22 Dec, 2017	US7762994
Patent Issue Date Used in PTA Calculation Critical	12 Nov, 2013	US8579869
Recordation of Patent Grant Mailed Critical	12 Nov, 2013	US8579869
Email Notification Critical	24 Oct, 2013	US8579869
Issue Notification Mailed Critical	23 Oct, 2013	US8579869
Dispatch to FDC	14 Oct, 2013	US8579869
Application Is Considered Ready for Issue Critical	08 Oct, 2013	US8579869
Printer Rush- No mailing	05 Oct, 2013	US8579869

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Novolog Flexpen and ongoing litigations to help you estimate the early arrival of Novolog Flexpen generic.

Novolog Flexpen's Litigations

Novolog Flexpen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 23, 2014, against patent number US9265893. The petitioner , challenged the validity of this patent, with Torben Stroem Hansen et al as the respondent. Click below to track the latest information on how companies are challenging Novolog Flexpen's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US9265893	January, 2014	Decision (08 Sep, 2015)	Torben Stroem Hansen et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Novolog Flexpen's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Novolog Flexpen's generic, the next section provides detailed information on ongoing and past EP oppositions related to Novolog Flexpen patents.

Novolog Flexpen's Oppositions Filed in EPO

Novolog Flexpen has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2010, by Sanofi-Aventis Deutschland Gmbh. This opposition was filed on patent number EP06121820A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP08708028A	Jul, 2011	Bock Wolfgang	Patent maintained as amended
EP06121820A	May, 2010	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected

US patents provide insights into the exclusivity only within the United States, but Novolog Flexpen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Novolog Flexpen's family patents as well as insights into ongoing legal events on those patents.

Novolog Flexpen's Family Patents

Novolog Flexpen has patent protection in a total of 14 countries. It's US patent count contributes only to 19.5% of its total global patent coverage. Click below to unlock the full patent family tree for Novolog Flexpen.

Unlock Global Patents

Generic Launch

About Novolog Flexpen

Novolog Flexpen is a drug owned by Novo Nordisk Inc. Novolog Flexpen uses Insulin Aspart Recombinant as an active ingredient. Novolog Flexpen was launched by Novo Nordisk Inc in 2013.